University of Ioannina
Καρδιακή δυσλειτουργία σε ασθενείς με χρόνια αποφρακτική πνευμονοπάθεια
Abstract
dc:descriptionPulmonary hypertension (PH) is defined as the elevation of mean pulmonary artery pressure above 25 mm Hg. Pulmonary arterial hypertension is a rather uncommon condition, while in the vast majority of patients with PH, elevated pressures in the pulmonary circulation are secondary to lung or heart disease, mainly chronic obstructive pulmonary disease (COPD) and left failure with reduced or preserved ejection fraction (HFrEF and HFpEF respectively). Τhe reported prevalence of PH in COPD patients varies depending on the severity of the disease and the selected definition of PH. Accumulating data suggest that in approximately 90% of patients with severe disease mean pulmonary artery pressure (mPAP) was more than 20 mm Hg, with most ranging between 20 and 35 mm Hg, while 3% to 5% of patients demonstrated mPAP > 35 to 40 mm Hg. Severe PH in COPD may be disproportionate to the degree of impairment of lung function. At the other end of the spectrum, in mild COPD and smokers with normal lung function, functional and structural changes of the pulmonary vascular bed have been documented. The pathogenesis of PH in COPD is multifactorial but not fully unfolded: it involves hypoxia, airway obstruction, a direct tobacco effect, and inflammation inducing vascular remodelling, and is associated with comorbidities, i.e. sleepdisorders, thromboembolism and left heart disease. Left heart disease is a well-known but often underdiagnosed co-morbidity of COPD. Pulmonary hypertension is a common complication of left heart disease and often related to disease severity, especially to HFpEF. Regardless of the aetiology of PH in COPD, severe PH is associated with an impaired outcome in such patients, and pulmonary artery pressure is the single most important predictor of mortality in COPD. Although the clinical diagnosis of PH in COPD is notoriously difficult and early diagnosis may potentially be beneficial in such patients, there are no clear guidelines for early or routine screening programmes in COPD.This prospective study aimed to look at the incidence and impact of PH as detected by echocardiography in COPD patients either stable or on exacerbation, and the interaction, ifany, between PH and left heart disease in COPD. Methods. All consecutive patients admitted either to the ICU or the Respiratory medicine ward of our hospital during one year-period (October 1, 2010- September 30, 2011) diagnosed with COPD exacerbation were eligible for the study. During the same time period we also enrolled consecutive stable COPD outpatients who gave their consent to take part in the study. Clinical evaluation: All patients underwent clinical examination, chest x-ray and electrocardiogram, and echocardiography examination was performed. Patients withechocardiographic evidence of left heart disease (valvular or structural), with abnormal ECG, as well as patients with normal findings but symptoms suggestive of coronary artery disease underwent a coronary angiography when indicated. The diagnosis of COPD was based on smoking history for at least 20 pack-years, the presence of symptoms compatible with COPD (dyspnea at rest or on exertion, coughing with or without sputum production, progressive limitation of activity), airflow limitation (postbronchodilator FEV1/FVC < 70 %), and a physical examination compatible with COPD. Acute exacerbation of COPD was defined as an increase in dyspnoea, coughing, and a change in sputum abundance and purulence. The definition of severe form of acute exacerbation ofCOPD was based on clinical and blood gas alterations, such as respiratory acidosis and anelevated bicarbonate level upon admission, change in the level of consciousness, and clinical signs of respiratory fatigue (respiratory rate > 25 breaths/min), paradoxical breathing andineffective cough. Patients in a stable stage underwent spirometry during their scheduled visit.Spirometric assessments were conducted in accordance with the American Thoracic Society–European Respiratory Society guidelines. Regarding patients with COPD exacerbation, the last spirometry, if performed in stable condition within the last 6 months before admission, was used. All patients were categorized regarding the stage of the severity of COPD based on the results of the spirometry according to international guidelines to the four COPD-GOLD stages. Echocardiographic examination: All out-hospital patients with stable COPD underwent echocardiography evaluation during routine examination. All patients with exacerbation of COPD underwent echocardiographical examination just after stabilisation (within the first 1-4 days after admission). Echo data was digitally recorded and the systolic function of the right (RV) and left ventricle (LV) function, as well as the presence of severe valvulopathy of the tricuspid, mitral and aortic valve, were assessed independently by two experienced echocardiographers and in case of disagreement an evaluation of the images was performed by a third echocardiographer. The presence of left heart failure was based upon echocardiographic criteria and defined as left heart failure with reduced ejection fraction (HFrEF) when evidence of heart failure was associated with a reduced ejection fraction of the left ventricle, and as left heart failure with preserved ejection fraction (HFpEF) when evidence of heart failure was associated with preserved ejection fraction with an abnormal pattern of mitral inflow pattern, i.e. E and A wave types, tissue velocities (e’), increased E/e’ ratio or increased atrial volume index (above 34mL/m2). Patients were evaluated by echocardiography for the presence of PH and/or right heart failure based on the maximum velocity of tricuspid regurgitation, TAPSE, dilatation and systolic dysfunction of RV, an increased RV end diastolic area to LV end diastolic area ratio (RVEDA/LVEDA ratio) in apical 4 chamber view and a dilatation of the right atrium andinferior vena cava. The likelihood of the presence of PH was based on echocardiographic findingsaccording to ESC guidelines. The presence of PH was characterized as likely when velocity oftricuspid regurgitation exceeded 3.4m/s, possible if velocity was 2.9-3.4m/s or ≤ 2.8m/s but with additional echocardiographic findings suggestive of PH, and unlikely if tricuspid regurgitation velocity was ≤ 2.8m/s with no other findings suggestive of PH. Patients with likely/possible PH according to echo criteria underwent right heart catheterization (RHC), if a written consent form was obtained, to confirm its presence and to further evaluate its cause and severity. In patients with confirmed PH and increased pulmonary artery occlusion pressure (PAOP) above 15mmHg in RHC, left heart disease is considered to be the cause of the PH. In these patients the diastolic pulmonary difference (DPD) was calculated. Patients with DPD<7mmHg were categorized as patients with isolated postcapillary PH, while patients with DPD≥7mmHg were categorized as patients with pre-/postcapillary PH. All patients were followed up for at least 6 months after study enrollment. Results. During the study period 140 patients were screened and finally 91 were enrolled. Thirty-nine (42.9%) were in a stable condition (group A) and 52 (57.1%) were patients with COPD exacerbation (group B). Patients in group A seem to be younger, in a better clinicalcondition and with less advanced COPD. Airway obstruction was more prominent in group B. There was no difference in the incidence of coronary artery disease, diabetes or hyperlipidemiabetween the two groups. Arterial hypertension was more common in group B. Patients with COPD exacerbation tended to have higher echocardiographically estimated systolic PAP, although this difference did not reach statistical significance. There was no significant difference in LV systolic function between the two groups, however there was a difference in LV diastolic dysfunction (53.8% vs 82.7% for group A and group B respectively, p=0.003). The incidence of LV hypertrophy was similar in both groups. There was no difference in the average left atrium area between the two groups. RV dilatation was significantly more common in group B (42.3% vs 18%, p=0.012). Longitudinal RV systolic function as expressed by TAPSE was preserved in both groups. Among the 91 patients, 45 (49.5%) fulfilled the ESC echo criteria for possible/likely PH. The incidence oflikely/possible PH was significantly higher in group B patients compared to group A (11/39 patients–28.2% vs 34/52 patients-65.4%, p=0.0001 in group A and B respectively). Regarding the total study population, patients with possible/likely PH were more likely to demonstrate LV diastolic dysfunction compared to patients with unlikely PH (80.0% vs 60.1% for patients with possible/likely and unlikely PH respectively, p=0.046). Patients with likely/possible PH were asked to undergo RHC to confirm the presence, severity and cause of PH. In 19 out of 34 group B patients with likely/possible PH a written consent was obtained and RHC was performed. In 15 out of these 19 patients the presence of PH was confirmed. While only in 4 out of these 15 patients the PAOP was ≤ 15 mm Hg indicating that PH was undependable of the left heart functionality, in the majority (11 out of 15, 73.3%) PAOP was > 15 mm Hg indicating PH is due to left heart disease (diastolicdysfunction was present in all 11 patients; in 5 of them systolic dysfunction was also present).Based on the DPD between the 11 patients, 6 demonstrated post-capillary PH (DPD < 7 mmHg) and 5 demonstrated combined pre- and post-capillary PH (DPD ≥ 7 mm Hg). Mortality: During the first 6 months after evaluation, 18 patients of group B died. Between the 18 deaths, 10 occurred during the initial hospitalization (in-hospital mortality, 19.2%) and 8 during the first 6 months (6-month mortality was 34.6%). Between the group B patients, the presence of possible/likely PH based on ESC criteria was associated with a statistically significant increase in mortality compared to those with unlikely PH (log Rank test chi square 6.7, p=0.009). Conclusion.In conclusion, the use of ESC echo criteria for the presence of PH seems to be adequate for screening COPD patients. Patients with AECOPD and possible/likely PH based on ESC echo criteria demonstrate worse mortality compared to patients with unlikely PH. The presence of heart failure (especially HFpEF) is evident in the vast majority of AECOPD patients with PH and is the cause of PH in the majority but not in all of these patients. Thus, patients with AECOPD and echo evidence for the presence of PH should undergo RHC to confirm the diagnosis and evaluate the cause of PH. Patients with PH due to left heart disease may be benefit from more aggressive HF therapy, while patients with PH not related to left heart disease may need further evaluation.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Roppa-Lepida, Dimitra
- Ρόππα-Λεπίδα, Δήμητρα
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46692